Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Beverly Moy(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Seth A. Wander(Massachusetts General Hospital), Andrzej Niemierko(Harvard University), Neelima Vidula(Harvard University), Leif W. Ellisen(Harvard University), Sara M. Tolaney(Dana-Farber Cancer Institute), Jennifer Goff(Harvard University), Elizabeth Abraham(Harvard University), Dejan Juric(Massachusetts General Hospital), Heather A. Parsons(Harvard University), Adrienne G. Waks(Harvard University), Steven J. Isakoff(Harvard University), Amanda Valenti(Harvard University), Mary McNeice(Harvard University)
Cited by 6
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983